Author: "Cattran D" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Cattran D"' showing total 265 results

Start Over Author "Cattran D"

265 results on '"Cattran D"'

1. Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.

Author: Bellur, Shubha S., primary, Troyanov, Stéphan, additional, Vorobyeva, Olga, additional, Coppo, Rosanna, additional, Roberts, Ian SD., additional, Cattran, D., additional, Cook, H.T., additional, Feehally, J., additional, Peruzzi, L., additional, Tesar, V., additional, Lunberg, S., additional, Gesualdo, L., additional, Emma, F., additional, Praga, M., additional, Feriozzi, S., additional, Pani, A., additional, Cancarini, G., additional, Durlik, M., additional, Moggia, E., additional, Giannakakis, C., additional, Honsova, E., additional, Sundelin, B.B., additional, Di Palma, A.M., additional, Ferrario, F., additional, Gutierrez, E., additional, Asunis, A.M., additional, Barratt, J., additional, Tardanico, R., additional, and Perkowska-Ptasinska, A., additional
Published: 2024
Full Text: View/download PDF

2. Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains

Author: Sedor, J., Dell, K., Schachere, M., Negrey, J., Lemley, K., Lim, E., Srivastava, T., Garrett, A., Sethna, C., Laurent, K., Appel, G., Toledo, M., Barisoni, L., Greenbaum, L., Wang, C., Kang, C., Adler, S., Nast, C., LaPage, J., Stroger, John H., Jr., Athavale, A., Itteera, M., Neu, A., Boynton, S., Fervenza, F., Hogan, M., Lieske, J., Chernitskiy, V., Kaskel, F., Kumar, N., Flynn, P., Kopp, J., Blake, J., Trachtman, H., Zhdanova, O., Modersitzki, F., Vento, S., Lafayette, R., Mehta, K., Gadegbeku, C., Johnstone, D., Quinn-Boyle, S., Cattran, D., Hladunewich, M., Reich, H., Ling, P., Romano, M., Fornoni, A., Bidot, C., Kretzler, M., Gipson, D., Williams, A., LaVigne, J., Derebail, V., Gibson, K., Froment, A., Grubbs, S., Holzman, L., Meyers, K., Kallem, K., Lalli, J., Sambandam, K., Wang, Z., Rogers, M., Jefferson, A., Hingorani, S., Tuttle, K., Bray, M., Kelton, M., Cooper, A., Freedman, B., Lin, J.J., Jayapandian, Catherine P., Chen, Yijiang, Janowczyk, Andrew R., Palmer, Matthew B., Cassol, Clarissa A., Sekulic, Miroslav, Hodgin, Jeffrey B., Zee, Jarcy, Hewitt, Stephen M., O’Toole, John, Toro, Paula, Sedor, John R., Barisoni, Laura, and Madabhushi, Anant
Published: 2021
Full Text: View/download PDF

3. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

Author: Lv, J, Wong, MG, Hladunewich, MA, Jha, V, Hooi, LS, Monaghan, H, Zhao, M, Barbour, S, Jardine, MJ, Reich, HN, Cattran, D, Glassock, R, Levin, A, Wheeler, DC, Woodward, M, Billot, L, Stepien, S, Rogers, K, Chan, TM, Liu, Z-H, Johnson, DW, Cass, A, Feehally, J, Floege, J, Remuzzi, G, Wu, Y, Agarwal, R, Zhang, H, Perkovic, V, and TESTING Study Group
Subjects: Adult, Male, Administration, Oral, Glomerulonephritis, IGA, Kidney, Methylprednisolone, Proteinuria, Double-Blind Method, Renal Dialysis, General & Internal Medicine, Disease Progression, Humans, Female, Renal Insufficiency, 11 Medical and Health Sciences
Abstract: Importance: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. Objective: To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. Design, Setting, and Participants: An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1.73 m2 after at least 3 months of optimized background care from 67 centers in Australia, Canada, China, India, and Malaysia between May 2012 and November 2019, with follow-up until June 2021. Interventions: Participants were randomized in a 1:1 ratio to receive oral methylprednisolone (initially 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning by 8 mg/d/mo; n = 136) or placebo (n = 126). After 262 participants were randomized, an excess of serious infections was identified, leading to dose reduction (0.4 mg/kg/d, maximum 32 mg/d, weaning by 4 mg/d/mo) and addition of antibiotic prophylaxis for pneumocystis pneumonia for subsequent participants (121 in the oral methylprednisolone group and 120 in the placebo group). Main Outcomes And Measures: The primary end point was a composite of 40% decline in eGFR, kidney failure (dialysis, transplant), or death due to kidney disease. There were 11 secondary outcomes, including kidney failure. Results: Among 503 randomized patients (mean age, 38 years; 198 [39%] women; mean eGFR, 61.5 mL/min/1.73 m2; mean proteinuria, 2.46 g/d), 493 (98%) completed the trial. Over a mean of 4.2 years of follow-up, the primary outcome occurred in 74 participants (28.8%) in the methylprednisolone group compared with 106 (43.1%) in the placebo group (hazard ratio [HR], 0.53 [95% CI, 0.39-0.72]; P
Published: 2022

4. Histological predictors of outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis

Author: Medjeral-Thomas, N, Barbour, S, Gisby, J, Han, H, Bomback, A, Fervenza, F, Cairns, T, Szydlo, R, Tan, S-J, Marks, S, Waters, A, Appel, G, D'Agati, V, Sethi, S, Nast, C, Bajema, I, Alpers, C, Fogo, A, Licht, C, Fakhouri, F, Cattran, D, Peters, J, Terence, C, Lomax-Browne, H, Pickering, M, and Alexion Pharmaceuticals Inc.
Subjects: urogenital system, 1103 Clinical Sciences, Urology & Nephrology
Abstract: Background and objectives C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis (Ig-MPGN) are kidney diseases characterised by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of patients reach end stage kidney disease within 10 years. Design, setting, participants and measurements To improve identification of patients with poor prognosis we performed a detailed analysis of percutaneous kidney biopsies in a large cohort of patients. Using a validated histological scoring system, we analysed 156 native diagnostic kidney biopsies from a retrospective cohort of 123 patients with C3 glomerulopathy and 33 patients with Ig-MPGN. We used linear regression, survival analysis and Cox proportional hazards models to assess the relationship between histological and clinical parameters with outcome. Results Frequent biopsy features were mesangial expansion and hypercellularity, glomerular basement membrane (GBM) double contours and endocapillary hypercellularity. Multivariable analysis showed negative associations between estimated glomerular filtration rate (eGFR) and crescents, interstitial inflammation, and interstitial fibrosis and tubular atrophy (IFTA). Proteinuria positively associated with endocapillary hypercellularity and GBM double contours. Analysis of second native biopsies did not demonstrate associations between immunosuppression treatment and improvement in histology. Using a composite outcome, risk of progression to kidney failure associated with eGFR and proteinuria at time of biopsy, and cellular/fibrocellular crescents, segmental sclerosis and IFTA scores. Conclusions Our detailed assessment of kidney biopsy data indicated that cellular/fibrocellular crescents and IFTA scores were significant determinants of deterioration in kidney function.
Published: 2022

5. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

Author: Coppo, R., D'Arrigo, G., Tripepi, G., Russo, M. L., Roberts, I. S. D., Bellur, S., Cattran, D., Cook, T. H., Feehally, J., Tesar, V., Maixnerova, D., Peruzzi, L., Amore, A., Lundberg, S., Di Palma, A. M., Gesualdo, L., Emma, F., Rollino, C., Praga, M., Biancone, L., Pani, A., Feriozzi, S., Polci, R., Barratt, J., Del Vecchio, L., Locatelli, F., Pierucci, A., Caliskan, Y., Perkowska-Ptasinska, A., Durlik, M., Moggia, E., Ballarin, J. C., Wetzels, J. F. M., Goumenos, D., Papasotiriou, M., Galesic, K., Toric, L., Papagianni, A., Stangou, M., Benozzi, L., Cusinato, S., Berg, U., Topaloglu, R., Maggio, M., Ots-Rosenberg, M., D'Amico, M., Geddes, C., Balafa, O., Quaglia, M., Cravero, R., Cirami, C. L., Fellstrom, B., Floege, J., Egido, J., Mallamaci, F., Zoccali, C., Fuiano, L., Beltrame, G., Camilla, R., Segoloni, G., Colla, L., Angioi, A., Piras, L., Cancarini, G., Ravera, S., Ballarin, J., Di Giulio, S., Pugliese, F., Serriello, I., Sever, M., Kilicaslan, I., Peters, H., Carvalho, F., Da Costa Ferreira, A. C., Wiecek, A., Magistroni, R., Bilginer, Y., Giacchino, F., Papastirou, M., Siamopoulos, K., Galliani, M., Stratta, P., Bergia, R., Salvadori, M., Cirami, L., Kloster Smerud, H., Ferrario, F., Stellato, T., Martin, C., Eitner, F., Rauen, T., Lupo, A., Bernich, P., Mene, P., Morosetti, M., Van Kooten, C., Rabelink, T., Reinders, M. E. J., Boria Grinyo, J. M., Savoldi, S., Licata, C., Mizerska-Wasiak, M., Roszkowska-Blaim, M., Martina, G., Messuerotti, A., Dal Canton, A., Esposito, C., Migotto, C., Triolo, G., Mariano, F., Pozzi, C., Boero, R., Mazzucco, G., Giannakakis, C., Honsova, E., Sundelin, B., Gutierrez, E., Asunis, A. M., Tardanico, R., Arce Terroba, J., Fortunato, M., Pantzaki, A., Ozluk, Y., Steenbergen, E., Soderberg, M., Riispere, Z., Furci, L., Orhan, D., Kipgen, D., Casartelli, D., Galesic Ljubanovic, D., Akiopoulou, H., Bertoni, E., Cannata Ortiz, P., Karkoszka, H., Groene, H. J., Stoppacciaro, A., Bajema, I., Bruijn, J., Fulladosa Oliveras, X., Maldyk, J., Ioachim, E., and Internal Medicine
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Adolescent, 030232 urology & nephrology, Renal function, 030204 cardiovascular system & hematology, Kidney, Nephropathy, Cohort Studies, 03 medical and health sciences, Glomerulonephritis, 0302 clinical medicine, renal biopsy, Interquartile range, IgA nephropathy, progression, risk factors, Child, Disease Progression, Female, Follow-Up Studies, Glomerular Filtration Rate, Glomerulonephritis, IGA, Humans, Prognosis, Medicine, Endocapillary hypercellularity, IGA, Transplantation, medicine.diagnostic_test, business.industry, medicine.disease, medicine.anatomical_structure, Renal pathology, Nephrology, Cohort, Renal biopsy, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business
Abstract: Background It is unknown whether renal pathology lesions in immunoglobulin A nephropathy (IgAN) correlate with renal outcomes over decades of follow-up. Methods In 1130 patients of the original Validation Study of the Oxford Classification for IgA Nephropathy (VALIGA) cohort, we studied the relationship between the MEST score (mesangial hypercellularity, M; endocapillary hypercellularity, E; segmental glomerulosclerosis, S; tubular atrophy/interstitial fibrosis, T), crescents (C) and other histological lesions with both a combined renal endpoint [50% estimated glomerular filtration rate (eGFR) loss or kidney failure] and the rate of eGFR decline over a follow-up period extending to 35 years [median 7 years (interquartile range 4.1–10.8)]. Results In this extended analysis, M1, S1 and T1–T2 lesions as well as the whole MEST score were independently related with the combined endpoint (P Conclusion Long-term follow-up analyses of the VALIGA cohort showed that the independent relationship between kidney biopsy findings and the risk of progression towards kidney failure in IgAN remains unchanged across all age groups and decades after the renal biopsy.
Published: 2020

6. Survival of the 'Ideal' Continuous Ambulatory Peritoneal Dialysis Patient

Author: Pei, Y., Bachtell, R., Fenton, S., Delmore, T., Johnson, N., Fulton, C., Copleston, P., Manuel, A., Cattran, D., Richardson, R., Avram, Morrell M., editor, Giordano, Carmelo, editor, DeSanto, Natale G., editor, Mittman, Neal, editor, Bazzato, Giorgio, editor, Fein, Paul A., editor, Gan, Amado, editor, Goldwasser, Philip, editor, and Slater, Paul A., editor
Published: 1990
Full Text: View/download PDF

7. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

Author: Canney, M., Barbour, S. J., Zheng, Y., Coppo, R., Zhang, H., Liu, Z. -H., Matsuzaki, K., Suzuki, Y., Katafuchi, R., Reich, H. N., Cattran, D., Russo, M. L., Troyanov, S., Cook, H. T., Roberts, I., Tesar, V., Maixnerova, D., Lundberg, S., Gesualdo, L., Emma, F., Fuiano, L., Beltrame, G., Rollino, C., Amore, A., Camilla, R., Peruzzi, L., Praga, M., Feriozzi, S., Polci, R., Segoloni, G., Colla, L., Pani, A., Piras, D., Angioi, A., Cancarini, G., Ravera, S., Durlik, M., Moggia, E., Ballarin, J., Di Giulio, S., Pugliese, F., Serriello, I., Caliskan, Y., Sever, M., Kilicaslan, I., Locatelli, F., Del Vecchio, L., Wetzels, J. F. M., Peters, H., Berg, U., Carvalho, F., da Costa Ferreira, A. C., Maggio, M., Wiecek, A., Ots-Rosenberg, M., Magistroni, R., Topaloglu, R., Bilginer, Y., D'Amico, M., Stangou, M., Giacchino, F., Goumenos, D., Kalliakmani, P., Gerolymos, M., Galesic, K., Geddes, C., Siamopoulos, K., Balafa, O., Galliani, M., Stratta, P., Quaglia, M., Bergia, R., Cravero, R., Salvadori, M., Cirami, L., Fellstrom, B., Kloster Smerud, H., Ferrario, F., Stellato, T., Egido, J., Martin, C., Floege, J., Eitner, F., Lupo, A., Bernich, P., Mene, P., Morosetti, M., van Kooten, C., Rabelink, T., Reinders, M. E. J., Boria Grinyo, J. M., Cusinato, S., Benozzi, L., Savoldi, S., Licata, C., Mizerska-Wasiak, M., Martina, G., Messuerotti, A., Dal Canton, A., Esposito, C., Migotto, C., Triolo, G., Mariano, F., Pozzi, C., Boero, R., Bellur, S., Mazzucco, G., Giannakakis, C., Honsova, E., Sundelin, B., Di Palma, A. M., Gutierrez, E., Asunis, A. M., Barratt, J., Tardanico, R., Perkowska-Ptasinska, A., Arce Terroba, J., Fortunato, M., Pantzaki, A., Ozluk, Y., Steenbergen, E., Soderberg, M., Riispere, Z., Furci, L., Orhan, D., Kipgen, D., Casartelli, D., Galesic Ljubanovic, D., Gakiopoulou, H., Bertoni, E., Cannata Ortiz, P., Karkoszka, H., Groene, H. J., Stoppacciaro, A., Bajema, I., Bruijn, J., Fulladosa Oliveras, X., Maldyk, J., Ioachim, E., Bavbek, N., Cook, T., Alpers, C., Feehally, J., Berthoux, F., Bonsib, S., D'Agati, V., D'Amico, G., Emancipator, S., Emmal, F., Fervenza, F., Florquin, S., Fogo, A., Groene, H., Haas, M., Hill, P., Hogg, R., Hsu, S., Hunley, T., Hladunewich, Jennette, C., Joh, K., Julian, B., Kawamura, T., Lai, F., Leung, C., Li, L., Li, P., Liu, Z., Massat, A., Mackinnon, B., Mezzano, S., Schena, F., Tomino, Y., Walker, P., Wang, H., Weening, J., Yoshikawa, N., Zeng, C. -H., Shi, S., Nogi, C., Suzuki, H., Koike, K., Hirano, K., Yokoo, T., Hanai, M., Fukami, K., Takahashi, K., Yuzawa, Y., Niwa, M., Yasuda, Y., Maruyama, S., Ichikawa, D., Suzuki, T., Shirai, S., Fukuda, A., Fujimoto, S., Trimarchi, H., Anesthesiology, Pathology, Graduate School, ACS - Heart failure & arrhythmias, and ACS - Atherosclerosis & ischemic syndromes
Subjects: Male, Time Factors, glomerular disease, 030232 urology & nephrology, 030204 cardiovascular system & hematology, Gastroenterology, 0302 clinical medicine, Outcome Assessment, Health Care, Clinical endpoint, Medicine, Clinical Epidemiology, Proteinuria, medicine.diagnostic_test, Remission Induction, Hazard ratio, IgA nephropathy, General Medicine, Middle Aged, end stage kidney disease, epidemiology and outcomes, proteinuria, renal function decline, renal pathology, 3. Good health, Renal pathology, Nephrology, Disease Progression, Female, medicine.symptom, Glomerular Filtration Rate, Adult, medicine.medical_specialty, Nephropathy, 03 medical and health sciences, Internal medicine, Biopsy, Humans, Proportional Hazards Models, Retrospective Studies, business.industry, Surrogate endpoint, Glomerulonephritis, IGA, medicine.disease, Confidence interval, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Kidney Failure, Chronic, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business
Abstract: Contains fulltext : 232930.pdf (Publisher’s version ) (Closed access) BACKGROUND: On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria needs to be maintained to mitigate the long-term risk of disease progression is unknown. METHODS: In this retrospective multiethnic cohort of adult patients with IgA nephropathy, we defined proteinuria remission as a ≥25% reduction in proteinuria from the peak value after biopsy, and an absolute reduction in proteinuria to
Published: 2021

8. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

Author: Canney, M. Barbour, S.J. Zheng, Y. Coppo, R. Zhang, H. Liu, Z.-H. Matsuzaki, K. Suzuki, Y. Katafuchi, R. Reich, H.N. Cattran, D. Russo, M.L. Troyanov, S. Cook, H.T. Roberts, I. Tesar, V. Maixnerova, D. Lundberg, S. Gesualdo, L. Emma, F. Fuiano, L. Beltrame, G. Rollino, C. Amore, A. Camilla, R. Peruzzi, L. Praga, M. Feriozzi, S. Polci, R. Segoloni, G. Colla, L. Pani, A. Piras, D. Angioi, A. Cancarini, G. Ravera, S. Durlik, M. Moggia, E. Ballarin, J. Di Giulio, S. Pugliese, F. Serriello, I. Caliskan, Y. Sever, M. Kilicaslan, I. Locatelli, F. Del Vecchio, L. Wetzels, J.F.M. Peters, H. Berg, U. Carvalho, F. da Costa Ferreira, A.C. Maggio, M. Wiecek, A. Ots-Rosenberg, M. Magistroni, R. Topaloglu, R. Bilginer, Y. D'Amico, M. Stangou, M. Giacchino, F. Goumenos, D. Kalliakmani, P. Gerolymos, M. Galesic, K. Geddes, C. Siamopoulos, K. Balafa, O. Galliani, M. Stratta, P. Quaglia, M. Bergia, R. Cravero, R. Salvadori, M. Cirami, L. Fellstrom, B. Kloster Smerud, H. Ferrario, F. Stellato, T. Egido, J. Martin, C. Floege, J. Eitner, F. Lupo, A. Bernich, P. Menè, P. Morosetti, M. van Kooten, C. Rabelink, T. Reinders, M.E.J. Boria Grinyo, J.M. Cusinato, S. Benozzi, L. Savoldi, S. Licata, C. Mizerska-Wasiak, M. Martina, G. Messuerotti, A. Dal Canton, A. Esposito, C. Migotto, C. Triolo, G. Mariano, F. Pozzi, C. Boero, R. Bellur, S. Mazzucco, G. Giannakakis, C. Honsova, E. Sundelin, B. Di Palma, A.M. Gutiérrez, E. Asunis, A.M. Barratt, J. Tardanico, R. Perkowska-Ptasinska, A. Arce Terroba, J. Fortunato, M. Pantzaki, A. Ozluk, Y. Steenbergen, E. Soderberg, M. Riispere, Z. Furci, L. Orhan, D. Kipgen, D. Casartelli, D. Galesic Ljubanovic, D. Gakiopoulou, H. Bertoni, E. Cannata Ortiz, P. Karkoszka, H. Groene, H.J. Stoppacciaro, A. Bajema, I. Bruijn, J. Fulladosa Oliveras, X. Maldyk, J. Ioachim, E. Bavbek, N. Cook, T. Alpers, C. Feehally, J. Berthoux, F. Bonsib, S. D'Agati, V. D'Amico, G. Emancipator, S. Emmal, F. Fervenza, F. Florquin, S. Fogo, A. Groene, H. Haas, M. Hill, P. Hogg, R. Hsu, S. Hunley, T. Hladunewich Jennette, C. Joh, K. Julian, B. Kawamura, T. Lai, F. Leung, C. Li, L. Li, P. Liu, Z. Massat, A. Mackinnon, B. Mezzano, S. Schena, F. Tomino, Y. Walker, P. Wang, H. Weening, J. Yoshikawa, N. Zeng, C.-H. Shi, S. Nogi, C. Suzuki, H. Koike, K. Hirano, K. Yokoo, T. Hanai, M. Fukami, K. Takahashi, K. Yuzawa, Y. Niwa, M. Yasuda, Y. Maruyama, S. Ichikawa, D. Suzuki, T. Shirai, S. Fukuda, A. Fujimoto, S. Trimarchi, H. International IgA Nephropathy Network
Abstract: Background On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria needs to be maintained to mitigate the long-term risk of disease progression is unknown. Methods In this retrospective multiethnic cohort of adult patients with IgA nephropathy, we defined proteinuria remission as a $25% reduction in proteinuria from the peak value after biopsy, and an absolute reduction in proteinuria to,1 g/d. The exposure of interest was the total duration of first remission, treated as a time-varying covariate using longitudinal proteinuria measurements. We used time-dependent Cox proportional hazards regression models to quantify the association between the duration of remission and the primary outcome (ESKD or a 50% reduction in eGFR). Results During a median follow-up of 3.9 years, 274 of 1864 patients (14.7%) experienced the primary outcome. The relationship between duration of proteinuria remission and outcome was nonlinear. Each 3 months in sustained remission up to approximately 4 years was associated with an additional 9% reduction in the risk of disease progression (hazard ratio [HR], 0.91; 95% confidence interval [95% CI], 0.89 to 0.93). Thereafter, each additional 3 months in remission was associated with a smaller, nonsignificant risk reduction (HR, 0.99; 95% CI, 0.96 to 1.03). These findings were robust to multivariable adjustment and consistent across clinical and histologic subgroups. Conclusions Our findings support the use of proteinuria as a surrogate outcome in IgA nephropathy, but additionally demonstrate the value of quantifying the duration of proteinuria remission when estimating the risk of hard clinical endpoints. Copyright © 2021 by the American Society of Nephrology.
Published: 2021

9. Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease.

Author: Carter S.A., Logeman C., Howell M., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D.J., Coppo R., Fervenza F.C., Floege J., Hladunewich M.A., Hogan J.J., Kitching A.R., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Cho Y., Dunn L., Gipson D.S., Liew A., Sautenet B., Viecelli A.K., Harris D., Johnson D.W., Wang A.Y.-M., Teixeira-Pinto A., Alexander S.I., Martin A., Tong A., Craig J.C., Carter S.A., Logeman C., Howell M., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D.J., Coppo R., Fervenza F.C., Floege J., Hladunewich M.A., Hogan J.J., Kitching A.R., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Cho Y., Dunn L., Gipson D.S., Liew A., Sautenet B., Viecelli A.K., Harris D., Johnson D.W., Wang A.Y.-M., Teixeira-Pinto A., Alexander S.I., Martin A., Tong A., and Craig J.C.
Abstract: Outcomes relevant to treatment decision-making are inconsistently reported in trials involving glomerular disease. Here, we sought to establish a consensus-derived set of critically important outcomes designed to be reported in all future trials by using an online, international two-round Delphi survey in English. To develop this, patients with glomerular disease, caregivers and health professionals aged 18 years and older rated the importance of outcomes using a Likert scale and a Best-Worst scale. The absolute and relative importance was assessed and comments were analyzed thematically. Of 1198 participants who completed Round 1, 734 were patients/caregivers while 464 were health care professionals from 59 countries. Of 700 participants that completed Round 2, 412 were patients/caregivers and 288 were health care professionals. Need for dialysis or transplant, kidney function, death, cardiovascular disease, remission-relapse and life participation were the most important outcomes to patients/caregivers and health professionals. Patients/caregivers rated patient-reported outcomes higher while health care professionals rated hospitalization, death and remission/relapse higher. Four themes explained the reasons for their priorities: confronting death and compounded suffering, focusing on specific targets in glomerular disease, preserving meaning in life, and fostering self-management. Thus, consistent reporting of these critically important outcomes in all trials involving glomerular disease is hoped to improve patient-centered decision-making.Copyright © 2021 International Society of Nephrology
Published: 2021

10. A Focus Group Study of Self-Management in Patients With Glomerular Disease.

Author: Carter S.A., Teng C., Gutman T., Logeman C., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D.J., Coppo R., Fervenza F.C., Floege J., Hladunewich M.A., Hogan J.J., Kitching A.R., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Azukaitis K., Cho Y., Viecelli A.K., Dunn L., Harris D., Johnson D.W., Kerr P.G., Laboi P., Ryan J., Shen J.I., Ruiz L., Wang A.Y.-M., Lee A.H.K., Ka Shun S.F., Ka-Hang Tong M., Teixeira-Pinto A., Wilkie M., Alexander S.I., Craig J.C., Martin A., Tong A., Carter S.A., Teng C., Gutman T., Logeman C., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D.J., Coppo R., Fervenza F.C., Floege J., Hladunewich M.A., Hogan J.J., Kitching A.R., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Azukaitis K., Cho Y., Viecelli A.K., Dunn L., Harris D., Johnson D.W., Kerr P.G., Laboi P., Ryan J., Shen J.I., Ruiz L., Wang A.Y.-M., Lee A.H.K., Ka Shun S.F., Ka-Hang Tong M., Teixeira-Pinto A., Wilkie M., Alexander S.I., Craig J.C., Martin A., and Tong A.
Abstract: Introduction: Patients with glomerular disease experience symptoms that impair their physical and mental health while managing their treatments, diet, appointments and monitoring general and specific indicators of health and their illness. We sought to describe the perspectives of patients and their care partners on self-management in glomerular disease. Method(s): We conducted 16 focus groups involving adult patients with glomerular disease (n = 101) and their care partners (n = 34) in Australia, Hong Kong, the United Kingdom, and United States. Transcripts were analyzed thematically. Result(s): We identified the following 4 themes: empowered in autonomy (gaining confidence through understanding, taking ownership of disease and treatment, learning a positive health approach); overwhelmed by compounding treatment burdens (financially undermined and depleted, demoralized by side effects and harms, frustrated by fragmented and inflexible care, fear of possible drug harms); striving for stability and normalcy (making personal sacrifices, maximizing life participation, attentiveness to bodily signs, avoiding precarious health states, integrating medicines into routines); and necessity of health-sustaining relationships (buoyed by social support, fulfilling meaningful responsibilities, sharing and normalizing experiences, seeking a trusting and respectful alliance). Conclusion(s): Patients with glomerular disease and their care partners value their capacity for autonomy and disease ownership, stability of their health, and relationships that support self-management. Strategies directed at strengthening these factors may increase self-efficacy and improve the care and outcomes for patients with glomerular disease.Copyright © 2021 International Society of Nephrology
Published: 2021

11. Tyne IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants

Author: Shulman, C, Liang, E, Kamura, M, Udwan, K, Yao, T, Cattran, D, Reich, H, Hladunewich, M, Pei, Y, Savige, J, Paterson, AD, Suico, MA, Kai, H, Barua, M, Shulman, C, Liang, E, Kamura, M, Udwan, K, Yao, T, Cattran, D, Reich, H, Hladunewich, M, Pei, Y, Savige, J, Paterson, AD, Suico, MA, Kai, H, and Barua, M
Abstract: RATIONALE & OBJECTIVE: Pathogenic variants in type IV collagen have been reported to account for a significant proportion of chronic kidney disease. Accordingly, genetic testing is increasingly used to diagnose kidney diseases, but testing also may reveal rare missense variants that are of uncertain clinical significance. To aid in interpretation, computational prediction (called in silico) programs may be used to predict whether a variant is clinically important. We evaluate the performance of in silico programs for COL4A3/A4/A5 variants. STUDY DESIGN SETTING & PARTICIPANTS: Rare missense variants in COL4A3/A4/A5 were identified in disease cohorts, including a local focal segmental glomerulosclerosis (FSGS) cohort and publicly available disease databases, in which they are categorized as pathogenic or benign based on clinical criteria. TESTS COMPARED & OUTCOMES: All rare missense variants identified in the 4 disease cohorts were subjected to in silico predictions using 12 different programs. Comparisons between the predictions were compared with: (1) variant classification (pathogenic or benign) in the cohorts and (2) functional characterization in a randomly selected smaller number (17) of pathogenic or uncertain significance variants obtained from the local FSGS cohort. RESULTS: In silico predictions correctly classified 75% to 97% of pathogenic and 57% to 100% of benign COL4A3/A4/A5 variants in public disease databases. The congruency of in silico predictions was similar for variants categorized as pathogenic and benign, with the exception of benign COL4A5 variants, in which disease effects were overestimated. By contrast, in silico predictions and functional characterization classified all 9 pathogenic COL4A3/A4/A5 variants correctly that were obtained from a local FSGS cohort. However, these programs also overestimated the effects of genomic variants of uncertain significance when compared with functional characterization. Each of the 12 in silico programs use
Published: 2021

12. POS-148 PROLONGING TIME IN REMISSION IN FSGS PATIENTS IMPACTS LONG-TERM OUTCOME

Author: JAUHAL, A., primary, Troyanov, S., additional, Reich, H., additional, Hladunewich, M., additional, Barua, M., additional, and Cattran, D., additional
Published: 2021
Full Text: View/download PDF

13. Identifying outcomes important to patients with glomerular disease and their caregivers

Author: Carter, S.A. Gutman, T. Logeman, C. Cattran, D. Lightstone, L. Bagga, A. Barbour, S.J. Barratt, J. Boletis, J. Caster, D. Coppo, R. Fervenza, F.C. Floege, J. Hladunewich, M. Hogan, J.J. Richard Kitching, A. Lafayette, R.A. Malvar, A. Radhakrishnan, J. Rovin, B.H. Scholes-Robertson, N. Trimarchi, H. Zhang, H. Azukaitis, K. Cho, Y. Viecelli, A.K. Dunn, L. Harris, D. Johnson, D.W. Kerr, P.G. Laboi, P. Ryan, J. Shen, J.I. Ruiz, L. Wang, A.Y.-M. Lee, A.H.K. Fung, S. Tong, M.K.-H. Teixeira-Pinto, A. Wilkie, M. Alexander, S.I. Craig, J.C. Tong, A.
Abstract: Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and caregivers and to describe reasons for their choices. Design, setting, participants, & measurements We purposively sampled adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. Participants identified, discussed, and ranked outcomes in focus groups using the nominal group technique; a relative importance score (between zero and one) was calculated. Qualitative data were analyzed thematically. Results Across 16 focus groups, 134 participants (range, 19–85 years old; 51%women), including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked out comes were kidney function(importance score of 0.42), mortality (0.29), need for dialysis or transplant (0.22), life participation (0.18), fatigue (0.17), anxiety (0.13), family impact (0.12), infection and immunity (0.12), ability to work (0.11), and BP (0.11). Three themes explained the reasons for these rankings: Constraining day-to-day experience, impaired agency and control over health, and threats to future health and family. Conclusions Patients with glomerular disease and their caregivers highly prioritize kidney health and survival, but they also prioritize life participation, fatigue, anxiety, and family impact. © 2020 by the American Society of Nephrology.
Published: 2020

14. Identifying outcomes important to patients with glomerular disease and their caregivers.

Author: Shen J.I., Tong M.K.-H., Teixeira-Pinto A., Wilkie M., Alexander S.I., Craig J.C., Tong A., Ryan J., Kerr P.G., Carter S.A., Gutman T., Logeman C., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D., Coppo R., Fervenza F.C., Floege J., Hladunewich M., Hogan J.J., Richard Kitching A., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Azukaitis K., Cho Y., Viecelli A.K., Dunn L., Harris D., Johnson D.W., Laboi P., Ruiz L., Wang A.Y.-M., Lee A.H.K., Fung S., Shen J.I., Tong M.K.-H., Teixeira-Pinto A., Wilkie M., Alexander S.I., Craig J.C., Tong A., Ryan J., Kerr P.G., Carter S.A., Gutman T., Logeman C., Cattran D., Lightstone L., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D., Coppo R., Fervenza F.C., Floege J., Hladunewich M., Hogan J.J., Richard Kitching A., Lafayette R.A., Malvar A., Radhakrishnan J., Rovin B.H., Scholes-Robertson N., Trimarchi H., Zhang H., Azukaitis K., Cho Y., Viecelli A.K., Dunn L., Harris D., Johnson D.W., Laboi P., Ruiz L., Wang A.Y.-M., Lee A.H.K., and Fung S.
Abstract: Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and caregivers and to describe reasons for their choices. Design, setting, participants, & measurements We purposively sampled adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. Participants identified, discussed, and ranked outcomes in focus groups using the nominal group technique; a relative importance score (between zero and one) was calculated. Qualitative data were analyzed thematically. Results Across 16 focus groups, 134 participants (range, 19-85 years old; 51%women), including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked out comes were kidney function(importance score of 0.42), mortality (0.29), need for dialysis or transplant (0.22), life participation (0.18), fatigue (0.17), anxiety (0.13), family impact (0.12), infection and immunity (0.12), ability to work (0.11), and BP (0.11). Three themes explained the reasons for these rankings: Constraining day-to-day experience, impaired agency and control over health, and threats to future health and family. Conclusions Patients with glomerular disease and their caregivers highly prioritize kidney health and survival, but they also prioritize life participation, fatigue, anxiety, and family impact.Copyright © 2020 by the American Society of Nephrology.
Published: 2020

15. Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains

Author: Jayapandian, Catherine P., primary, Chen, Yijiang, additional, Janowczyk, Andrew R., additional, Palmer, Matthew B., additional, Cassol, Clarissa A., additional, Sekulic, Miroslav, additional, Hodgin, Jeffrey B., additional, Zee, Jarcy, additional, Hewitt, Stephen M., additional, O’Toole, John, additional, Toro, Paula, additional, Sedor, John R., additional, Barisoni, Laura, additional, Madabhushi, Anant, additional, Sedor, J., additional, Dell, K., additional, Schachere, M., additional, Negrey, J., additional, Lemley, K., additional, Lim, E., additional, Srivastava, T., additional, Garrett, A., additional, Sethna, C., additional, Laurent, K., additional, Appel, G., additional, Toledo, M., additional, Barisoni, L., additional, Greenbaum, L., additional, Wang, C., additional, Kang, C., additional, Adler, S., additional, Nast, C., additional, LaPage, J., additional, Stroger, John H., additional, Athavale, A., additional, Itteera, M., additional, Neu, A., additional, Boynton, S., additional, Fervenza, F., additional, Hogan, M., additional, Lieske, J., additional, Chernitskiy, V., additional, Kaskel, F., additional, Kumar, N., additional, Flynn, P., additional, Kopp, J., additional, Blake, J., additional, Trachtman, H., additional, Zhdanova, O., additional, Modersitzki, F., additional, Vento, S., additional, Lafayette, R., additional, Mehta, K., additional, Gadegbeku, C., additional, Johnstone, D., additional, Quinn-Boyle, S., additional, Cattran, D., additional, Hladunewich, M., additional, Reich, H., additional, Ling, P., additional, Romano, M., additional, Fornoni, A., additional, Bidot, C., additional, Kretzler, M., additional, Gipson, D., additional, Williams, A., additional, LaVigne, J., additional, Derebail, V., additional, Gibson, K., additional, Froment, A., additional, Grubbs, S., additional, Holzman, L., additional, Meyers, K., additional, Kallem, K., additional, Lalli, J., additional, Sambandam, K., additional, Wang, Z., additional, Rogers, M., additional, Jefferson, A., additional, Hingorani, S., additional, Tuttle, K., additional, Bray, M., additional, Kelton, M., additional, Cooper, A., additional, Freedman, B., additional, and Lin, J.J., additional
Published: 2021
Full Text: View/download PDF

16. Larger Recipient Body Mass Index Is Associated with an Increased Risk of Adverse Outcomes after Kidney Transplantation.: Abstract# 732 Poster Board #-Session: P200-I

Author: Curran, S. P., Famure, O., Cardella, C. J., Cattran, D. C., Cole, E. H., Schiff, J., Tinckam, K. J., and Kim, J.
Published: 2012

17. Increased Time-Dependent Variability in Tacrolimus Levels Is Associated with Inferior Outcomes Following Kidney Transplantation.: Abstract# 302

Author: Sapir-Pichhadze, R., Wang, Y., Famure, O., Li, Y., Cardella, C. J., Cattran, D. C., Cole, E. H., Schiff, J., Tinckam, K. J., and Kim, J.
Published: 2012

18. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: Evidence from the VALidation of IGA study cohort

Author: Bellur, S.S. Roberts, I.S.D. Troyanov, S. Royal, V. Coppo, R. Cook, H.T. Cattran, D. Terroba, Y.A. Asunis, A.M. Bajema, I. Bertoni, E. Bruijn, J.A. Cannata-Ortiz, P. Casartelli, D. Di Palma, A.M. Ferrario, F. Fortunato, M. Furci, L. Gakiopoulou, H. Ljubanovic, D.G. Giannakakis, K. Gomá, M. Gröne, H.-J. Gutiérrez, E. Haider, S.A. Honsova, E. Ioachim, E. Karkoszka, H. Kipgen, D. Maldyk, J. Mazzucco, G. Orhan, D. Ozluk, Y. Pantzaki, A. Perkowska-Ptasinska, A. Riispere, Z. Soderberg, M.P. Steenbergen, E. Stoppacciaro, A. Von Feilitzen, B.S. Tardanico, R. Tesar, V. Maixnerova, D. Lundberg, S. Gesualdo, L. Emma, F. Fuiano, L. Beltrame, G. Rollino, C. Coppo, R. Amore, A. Camilla, R. Peruzzi, L. Praga, M. Feriozzi, S. Polci, R. Segoloni, G. Colla, L. Pani, A. Angioi, A. Piras, L. Feehally, J. Barratt, J. Cancarini, G. Ravera, S. Durlik, M. Moggia, E. Ballarin, J. Di Giulio, S. Pugliese, F. Serriello, I. Caliskan, Y. Sever, M. Locatelli, F. Del Vecchio, L. Wetzels, J.F.M. Peters, H. Berg, U. Carvalho, F. da Costa Ferreira, A.C. Maggio, M. Wiecek, A. Ots-Rosenberg, M. Magistroni, R. Topaloglu, R. Bilginer, Y. D'Amico, M. Stangou, M. Giacchino, F. Goumenos, D. Kalliakmani, P. Gerolymos, M. Galesic, K. Geddes, C. Siamopoulos, K. Balafa, O. Galliani, M. Stratta, P. Quaglia, M. Bergia, R. Cravero, R. Salvadori, M. Cirami, L. Fellstrom, B. Kloster Smerud, H. Ferrario, F. Stellato, T. Egido, J. Martin, C. Floege, J. Eitner, F. Lupo, A. Bernich, P. Menè, P. Morosetti, M. van Kooten, C. Rabelink, T. Reinders, M.E.J. Grinyo, J.M. Fulladosa, X. Cusinato, S. Benozzi, L. Savoldi, S. Licata, C. Mizerska-Wasiak, M. Roszkowska-Blaim, M. Martina, G. Messuerotti, A. Dal Canton, A. Esposito, C. Migotto, C. Triolo, G. Mariano, F. Pozzi, C. Boero, R. Kilicaslan, I.
Abstract: Background: The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. Results: All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). Conclusion: We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies. © 2018 The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Published: 2019

19. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: Evidence from the VALidation of IGA study cohort

Author: Bellur, S. S., Roberts, I. S. D., Troyanov, S., Royal, V., Coppo, R., Cook, H. T., Cattran, D., Terroba, Y. A., Asunis, A. M., Bajema, I., Bertoni, E., Bruijn, J. A., Cannata-Ortiz, P., Casartelli, D., Di Palma, A. M., Ferrario, F., Fortunato, M., Furci, L., Gakiopoulou, H., Ljubanovic, D. G., Giannakakis, K., Goma, M., Grone, H. -J., Gutierrez, E., Haider, S. A., Honsova, E., Ioachim, E., Karkoszka, H., Kipgen, D., Maldyk, J., Mazzucco, G., Orhan, D., Ozluk, Y., Pantzaki, A., Perkowska-Ptasinska, A., Riispere, Z., Soderberg, M. P., Steenbergen, E., Stoppacciaro, A., Von Feilitzen, B. S., Tardanico, R., Tesar, V., Maixnerova, D., Lundberg, S., Gesualdo, L., Emma, F., Fuiano, L., Beltrame, G., Rollino, C., Amore, A., Camilla, R., Peruzzi, L., Praga, M., Feriozzi, S., Polci, R., Segoloni, G., Colla, L., Pani, A., Angioi, A., Piras, L., Feehally, J., Barratt, J., Cancarini, G., Ravera, S., Durlik, M., Moggia, E., Ballarin, J., Di Giulio, S., Pugliese, F., Serriello, I., Caliskan, Y., Sever, M., Locatelli, F., Del Vecchio, L., Wetzels, J. F. M., Peters, H., Berg, U., Carvalho, F., da Costa Ferreira, A. C., Maggio, M., Wiecek, A., Ots-Rosenberg, M., Magistroni, R., Topaloglu, R., Bilginer, Y., D'Amico, M., Stangou, M., Giacchino, F., Goumenos, D., Kalliakmani, P., Gerolymos, M., Galesic, K., Geddes, C., Siamopoulos, K., Balafa, O., Galliani, M., Stratta, P., Quaglia, M., Bergia, R., Cravero, R., Salvadori, M., Cirami, L., Fellstrom, B., Kloster Smerud, H., Stellato, T., Egido, J., Martin, C., Floege, J., Eitner, F., Lupo, A., Bernich, P., Mene, P., Morosetti, M., van Kooten, C., Rabelink, T., Reinders, M. E. J., Grinyo, J. M., Fulladosa, X., Cusinato, S., Benozzi, L., Savoldi, S., Licata, C., Mizerska-Wasiak, M., Roszkowska-Blaim, M., Martina, G., Messuerotti, A., Dal Canton, A., Esposito, C., Migotto, C., Triolo, G., Mariano, F., Pozzi, C., Boero, R., and Kilicaslan, I.
Subjects: medicine.medical_specialty, IgA nephropathy, immunosuppression, kidney biopsy, Oxford classification, proteinuria, medicine.medical_treatment, Biopsy, 030232 urology & nephrology, Disease, 030204 cardiovascular system & hematology, Lesion, 03 medical and health sciences, 0302 clinical medicine, Glomerulonephritis, Models, Internal medicine, medicine, Humans, Endocapillary hypercellularity, Clinical significance, IGA, Retrospective Studies, Observer Variation, Transplantation, Models, Statistical, Proteinuria, medicine.diagnostic_test, business.industry, Patient Selection, Oxford classification, Reproducibility of Results, Glomerulonephritis, IGA, Immunosuppression, Statistical, Prognosis, Nephrology, proteinuria, Glomerular Filtration Rate, Immunosuppressive Agents, Cohort, medicine.symptom, business
Abstract: Background The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. Results All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). Conclusion We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
Published: 2019

20. Renal pathology in idiopathic membranous nephropathy: A new perspective

Author: Troyanov, S, Roasio, L, Pandes, M, Herzenberg, A M, and Cattran, D C
Published: 2006

21. Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Author: Ryan J., Alexander S.I., Cho Y., Craig J.C., Harris D., Johnson D.W., Kerr P.G., Viecelli A.K., Wang A.Y.-M., Wilkie M., Scholes-Robertson N., Tong A., Carter S.A., Lightstone L., Cattran D., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D., Coppo R., Fervenza F.C., Floege J., Hladunewich M., Hogan J.J., Kitching A.R., Lafayette R., Malvar A., Radhakrishnan J., Rovin B.H., Zhang H., Gutman T., Howell M., Logeman C., Shen J.I., Teixeira-Pinto A., Ryan J., Alexander S.I., Cho Y., Craig J.C., Harris D., Johnson D.W., Kerr P.G., Viecelli A.K., Wang A.Y.-M., Wilkie M., Scholes-Robertson N., Tong A., Carter S.A., Lightstone L., Cattran D., Bagga A., Barbour S.J., Barratt J., Boletis J., Caster D., Coppo R., Fervenza F.C., Floege J., Hladunewich M., Hogan J.J., Kitching A.R., Lafayette R., Malvar A., Radhakrishnan J., Rovin B.H., Zhang H., Gutman T., Howell M., Logeman C., Shen J.I., and Teixeira-Pinto A.
Published: 2019

22. Reproducibility of the Oxford Classification of IgA nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALIGA study cohort

Author: Bellur, S, Roberts, ISD, Troyanov, S, Royal, V, Coppo, R, Cook, HT, Cattran, D, Terroba, YA, Asunis, AM, Bajema, I, Bertoni, E, Bruijn, JA, Cannata-Ortiz, P, Casartelli, D, Di Palma, AM, Ferrario, F, Fortunato, M, Furci, L, Gakiopoulou, H, Ljubanovic, DG, Giannakakis, K, Gomà, M, Gröne, H-J, Gutiérrez, E, Haider, SA, Honsova, E, Ioachim, E, Karkoszka, H, Kipgen, D, Maldyk, J, Mazzucco, G, Orhan, D, Ozluk, Y, Pantzaki, A, Perkowska-Ptasinska, A, Riispere, Z, Soderberg, M, Steenbergen, E, Stoppacciaro, A, Sundelin, B, and Tardanico, R
Subjects: immunosuppression, kidney biopsy, Oxford classification, 1103 Clinical Sciences, IgA nephropathy, proteinuria, Urology & Nephrology
Abstract: Objective & Methods: The VALIGA study investigated the utility of the Oxford Classification of IgA nephropathy (IgAN) in 1147 patients from 13 European countries. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive treatments (CS/IS), and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present-central absent, local absent-central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. Results: All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy whilst the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity), and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. By contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes compared to central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). Conclusion: We conclude that differences in the scoring of MEST-C criteria between local pathologists and central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
Published: 2018

23. SUN-019 IDENTIFYING OUTCOMES IMPORTANT TO PATIENTS WITH GLOMERULONEPHRITIS AND THEIR CAREGIVERS: A MULTINATIONAL NOMINAL GROUP STUDY

Author: CARTER, S., primary, Gutman, T., additional, Logeman, C., additional, Cattran, D., additional, Lightstone, L., additional, Shen, J., additional, Wang, A., additional, Wilkie, M., additional, Craig, J., additional, and Tong, A., additional
Published: 2019
Full Text: View/download PDF

24. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort

Author: Coppo, R., Lofaro, D., Camilla, R.R., Bellur, S., Cattran, D., Cook, H.T., Roberts, I.S., Peruzzi, L., Amore, A., Emma, F., Fuiano, L., Berg, U., Topaloglu, R., Bilginer, Y., Gesualdo, L., Polci, R., Mizerska-Wasiak, M., Caliskan, Y., Lundberg, S., Cancarini, G., Geddes, C., Wetzels, J., Wiecek, A., Durlik, M., Cusinato, S., Rollino, C., Maggio, M., Praga, M., Smerud, H.K., Tesar, V., Maixnerova, D., Barratt, J., Papalia, T., Bonofiglio, R., Mazzucco, G., Giannakakis, C., Soderberg, M., Orhan, D., Palma, A.M. De, Maldyk, J., Ozluk, Y., Sudelin, B., Tardanico, R., Kipgen, D., Steenbergen, E., Karkoszka, H., Perkowska-Ptasinska, A., Ferrario, F., Gutierrez, E., Honsova, E., Coppo, R., Lofaro, D., Camilla, R.R., Bellur, S., Cattran, D., Cook, H.T., Roberts, I.S., Peruzzi, L., Amore, A., Emma, F., Fuiano, L., Berg, U., Topaloglu, R., Bilginer, Y., Gesualdo, L., Polci, R., Mizerska-Wasiak, M., Caliskan, Y., Lundberg, S., Cancarini, G., Geddes, C., Wetzels, J., Wiecek, A., Durlik, M., Cusinato, S., Rollino, C., Maggio, M., Praga, M., Smerud, H.K., Tesar, V., Maixnerova, D., Barratt, J., Papalia, T., Bonofiglio, R., Mazzucco, G., Giannakakis, C., Soderberg, M., Orhan, D., Palma, A.M. De, Maldyk, J., Ozluk, Y., Sudelin, B., Tardanico, R., Kipgen, D., Steenbergen, E., Karkoszka, H., Perkowska-Ptasinska, A., Ferrario, F., Gutierrez, E., and Honsova, E.
Abstract: Item does not contain fulltext
Published: 2017

25. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial

Author: Lv, J, Zhang, H, Wong, MG, Jardine, MJ, Hladunewich, M, Jha, V, Monaghan, H, Zhao, M, Barbour, S, Reich, H, Cattran, D, Glassock, R, Levin, A, Wheeler, D, Woodward, M, Billot, L, Chan, TM, Liu, ZH, Johnson, DW, Cass, A, Feehally, J, Floege, J, Remuzzi, G, Wu, Y, Agarwal, R, Wang, HY, Perkovic, V, Lv, J, Zhang, H, Wong, MG, Jardine, MJ, Hladunewich, M, Jha, V, Monaghan, H, Zhao, M, Barbour, S, Reich, H, Cattran, D, Glassock, R, Levin, A, Wheeler, D, Woodward, M, Billot, L, Chan, TM, Liu, ZH, Johnson, DW, Cass, A, Feehally, J, Floege, J, Remuzzi, G, Wu, Y, Agarwal, R, Wang, HY, and Perkovic, V
Abstract: IMPORTANCE: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. OBJECTIVE: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. DESIGN, SETTING, AND PARTICIPANTS: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred. INTERVENTIONS: Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8 mg/kg/d; maximum, 48 mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent weaning over 4 to 6 months. MAIN OUTCOMES AND MEASURES: The primary composite outcome was end-stage kidney disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis, and cardiovascular events. The mean required follow-up was estimated to be 5 years. RESULTS: After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%] women; eGFR, 59.4 mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years’ median follow-up, recruitment was discontinued because of excess serious adverse events. Serious events occurred in 20 participants (14.7%) in the methylprednisolone group vs 4 (3.2%) in the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%]; P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in the methylprednisolone group vs 20 (15.9%) in the placeb
Published: 2017

26. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy

Author: Haas, M. de, Verhave, J.C., Liu, Z.H., Alpers, C.E., Barratt, J., Becker, J.U., Cattran, D., Cook, H.T., Coppo, R., Feehally, J., Pani, A., Perkowska-Ptasinska, A., Roberts, I.S., Soares, M.F., Trimarchi, H., Wang, S., Yuzawa, Y., Zhang, H., Troyanov, S., Katafuchi, R., Haas, M. de, Verhave, J.C., Liu, Z.H., Alpers, C.E., Barratt, J., Becker, J.U., Cattran, D., Cook, H.T., Coppo, R., Feehally, J., Pani, A., Perkowska-Ptasinska, A., Roberts, I.S., Soares, M.F., Trimarchi, H., Wang, S., Yuzawa, Y., Zhang, H., Troyanov, S., and Katafuchi, R.
Abstract: Item does not contain fulltext, The Oxford Classification of IgA nephropathy does not account for glomerular crescents. However, studies that reported no independent predictive role of crescents on renal outcomes excluded individuals with severe renal insufficiency. In a large IgA nephropathy cohort pooled from four retrospective studies, we addressed crescents as a predictor of renal outcomes and determined whether the fraction of crescent-containing glomeruli associates with survival from either a >/=50% decline in eGFR or ESRD (combined event) adjusting for covariates used in the original Oxford study. The 3096 subjects studied had an initial mean+/-SD eGFR of 78+/-29 ml/min per 1.73 m2 and median (interquartile range) proteinuria of 1.2 (0.7-2.3) g/d, and 36% of subjects had cellular or fibrocellular crescents. Overall, crescents predicted a higher risk of a combined event, although this remained significant only in patients not receiving immunosuppression. Having crescents in at least one sixth or one fourth of glomeruli associated with a hazard ratio (95% confidence interval) for a combined event of 1.63 (1.10 to 2.43) or 2.29 (1.35 to 3.91), respectively, in all individuals. Furthermore, having crescents in at least one fourth of glomeruli independently associated with a combined event in patients receiving and not receiving immunosuppression. We propose adding the following crescent scores to the Oxford Classification: C0 (no crescents); C1 (crescents in less than one fourth of glomeruli), identifying patients at increased risk of poor outcome without immunosuppression; and C2 (crescents in over one fourth of glomeruli), identifying patients at even greater risk of progression, even with immunosuppression.
Published: 2017

27. Ciclosporin in Glomerulonephritis — A Pilot Study

Author: Cattran, D. C., Dossetor, J., Halloran, P. F., Cardella, C., Stiller, C., Keown, P., Clark, W. F., and Schindler, Rosemarie, editor
Published: 1985
Full Text: View/download PDF

28. Tonsillectomy in a European Cohort of 1, 147 Patients with IgA Nephropathy

Author: Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, Roberts IS, Verhave JC, Camilla R, Vergano L, Egido J, Wiecek A, Karkoszka H, Tesar V, Maixnerova D, Ots- Rosenberg M, Quaglia M, Rollino C, Magistroni R, Cusinato S, Cravero R, Peruzzi L, Lundberg S, Gesualdo L, Cancarini G, Feriozzi S, Ferrario F, and VALIGA study of ERA-EDTA Immunonephrology Working Group
Subjects: urologic and male genital diseases, Tonsillectomy, IgA Nephropathy, VALIGA
Abstract: BACKGROUND: Tonsillectomy has been considered a treatment for IgA nephropathy (IgAN). It is aimed at removing a source of pathogens, reducing mucosa-associated lymphoid tissue and decreasing polymeric IgA synthesis. However, its beneficial effect is still controversial. In Asia, favorable outcomes have been claimed mostly in association with corticosteroids. In Europe, small, single- center uncontrolled studies have failed to show benefits. METHODS: The European validation study of the Oxford classification of IgAN (VALIGA) collected data from 1, 147 patients with IgAN over a follow-up of 4.7 years. We investigated the outcome of progression to end-stage renal disease (ESRD) and/or 50% loss of estimated glomerular filtration rate (eGFR) and the annual loss of eGFR in 61 patients who had had tonsillectomy. RESULTS: Using the propensity score, which is a logistic regression model, we paired 41 patients with tonsillectomy and 41 without tonsillectomy with similar risk of progression (gender, age, race, mean blood pressure, proteinuria, eGFR at renal biopsy, previous treatments and Oxford MEST scores). No significant difference was found in the outcome. Moreover, we performed an additional propensity score pairing 17 patients who underwent tonsillectomy after the diagnosis of IgAN and 51 without tonsillectomy with similar risk of progression at renal biopsy and subsequent treatments. No significant difference was found in changes in proteinuria, or in the renal end point of 50% reduction in GFR and/or ESRD, or in the annual loss of eGFR. CONCLUSION: In the large VALIGA cohort of European subjects with IgAN, no significant correlation was found between tonsillectomy and renal function decline.
Published: 2016

29. Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy

Author: Feehally, J, Coppo, R, Troyanov, S, Bellur, Ss, Cattran, D, Cook, T, Roberts, Is, Verhave, Jc, Camilla, R, Vergano, L, Egido, J, Wiecek, A, Karkoszka, H, Tesar, V, Maixnerova, D, Ots-Rosenberg, M, Quaglia, M, Rollino, C, Magistroni, R, Cusinato, S, Cravero, R, Peruzzi, L, Lundberg, S, Gesualdo, L, Cancarini, G, Feriozzi, S, Ferrario, F, Emma, F, Fuiano, L, Beltrame, G, Amore, A, Praga, M, Polci, R, Biancone, L, Colla, L, Pani, A, Angioi, A, Piras, D, Ravera, S, Durlik, M, Moggia, E, Ballarin, J, Di Giulio, S, Pierucci, A, Caliskan, Y, Sever, M, Kilicaslan, I, Locatelli, F, Del Vecchio, L, Wetzels, Jf, Peters, H, Berg, U, Carvalho, F, da Costa Ferreira AC, Maggio, M, Topaloglu, R, Bilginer, Y, D'Amico, M, Stangou, M, Giacchino, F, Goumenos, D, Kalliakmani, P, Gerolymos, M, Galesic, K, Geddes, C, Siamopoulos, K, Balafa, O, Galliani, M, Stratta, P, Bergia, R, Salvadori, M, Cirami, L, Fellstrom, B, Kloster Smerud, H, Stellato, T, Cleary, C, Floege, J, Rauen, T, Lupo, A, Bernich, P, Menè, P, Morosetti, M, van Kooten, C, Rabelink, T, Reinders, Me, Boria Grinyo JM, Benozzi, L, Savoldi, S, Licata, C, Mizerska-Wasiak, M, Roszkowska-Blaim, M, Martina, G, Messuerotti, A, Dal Canton, A, Esposito, C, Migotto, C, Triolo, G, Mariano, F, Pozzi, C, Di Palma AM, Boero, R, Mazzucco, G, Giannakakis, C, Honsova, E, Sundelin, B, Gutiérrez, E, Asunis, Am, Barratt, J, Tardanico, R, Perkowska-Ptasinska, A, Arce Terroba, J, Fortunato, M, Pantzaki, A, Ozluk, Y, Steenbergen, E, Soderberg, M, Riispere, Z, Furci, L, Orhan, D, Kipgen, D, Casartelli, D, Galesic Ljubanovic, D, Gakiopoulou, H, Bertoni, E, Cannata Ortiz, P, Groene, Hj, Stoppacciaro, A, Bajema, I, Bruijn, J, Fulladosa Oliveras, X, Maldyk, J, and Ioachim, E.
Subjects: Male, Physiology, medicine.medical_treatment, IgA nephropathy, Tonsillectomy, Risk factors, Progression of chronic renal failure, 030232 urology & nephrology, 030204 cardiovascular system & hematology, urologic and male genital diseases, Gastroenterology, Progression of chronic renal failure, Cohort Studies, Kidney Failure, Glomerulonephritis, 0302 clinical medicine, Ethnicity, Chronic, Proteinuria, medicine.diagnostic_test, Age Factors, IgA nephropathy, Middle Aged, Europe, Treatment Outcome, Nephrology, Cohort, Disease Progression, Female, Renal biopsy, medicine.symptom, Glomerular Filtration Rate, Cohort study, Adult, medicine.medical_specialty, Urology, Renal function, Ethnic Groups, Nephropathy, iga nephropathy, tonsillectomy, risk factors, progression of chronic renal failure, 03 medical and health sciences, Sex Factors, Physiology (medical), Internal medicine, Risk factors, Tonsillectomy, medicine, Humans, Follow-Up Studies, Glomerulonephritis, IGA, Kidney Failure, Chronic, Propensity Score, Retrospective Studies, IGA, business.industry, Retrospective cohort study, medicine.disease, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business
Abstract: Background: Tonsillectomy has been considered a treatment for IgA nephropathy (IgAN). It is aimed at removing a source of pathogens, reducing mucosa-associated lymphoid tissue and decreasing polymeric IgA synthesis. However, its beneficial effect is still controversial. In Asia, favorable outcomes have been claimed mostly in association with corticosteroids. In Europe, small, single-center uncontrolled studies have failed to show benefits. Methods: The European validation study of the Oxford classification of IgAN (VALIGA) collected data from 1,147 patients with IgAN over a follow-up of 4.7 years. We investigated the outcome of progression to end-stage renal disease (ESRD) and/or 50% loss of estimated glomerular filtration rate (eGFR) and the annual loss of eGFR in 61 patients who had had tonsillectomy. Results: Using the propensity score, which is a logistic regression model, we paired 41 patients with tonsillectomy and 41 without tonsillectomy with similar risk of progression (gender, age, race, mean blood pressure, proteinuria, eGFR at renal biopsy, previous treatments and Oxford MEST scores). No significant difference was found in the outcome. Moreover, we performed an additional propensity score pairing 17 patients who underwent tonsillectomy after the diagnosis of IgAN and 51 without tonsillectomy with similar risk of progression at renal biopsy and subsequent treatments. No significant difference was found in changes in proteinuria, or in the renal end point of 50% reduction in GFR and/or ESRD, or in the annual loss of eGFR. Conclusion: In the large VALIGA cohort of European subjects with IgAN, no significant correlation was found between tonsillectomy and renal function decline.
Published: 2016

30. SP104IS THERE LONG-TERM VALUE OF PATHOLOGY SCORING IN IGA NEPHROPATHY? A VALIGA UPDATE

Author: Coppo, Rosanna, primary, D'Arrigo, G, additional, Tripepi, G, additional, Russo, ML, additional, Roberts, I.S.D, additional, Bellur, S, additional, Cattran, D, additional, Cook, TH, additional, Feehally, J, additional, Tesar, V, additional, Maixnerova, D, additional, Lundberg, S, additional, Di Palma, AM, additional, Emma, F, additional, Rollino, C, additional, Praga, M, additional, Biancone, L, additional, Pani, A, additional, Barratt, J, additional, Del Vecchio, L, additional, Locatelli, F, additional, Pierucci, A, additional, Caliskan, Y, additional, Perkowska-Ptasinska, A, additional, and Ballarin, J, additional
Published: 2017
Full Text: View/download PDF

31. Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy

Author: Feehally, J., Coppo, R., Troyanov, S., Bellur, S.S., Cattran, D., Cook, T., Roberts, I.S., Verhave, J.C., Camilla, R., Vergano, L., Egido, J., Wiecek, A., Karkoszka, H., Tesar, V., Maixnerova, D., Ots-Rosenberg, M., Quaglia, M., Rollino, C., Magistroni, R., Cusinato, S., Cravero, R., Peruzzi, L., Lundberg, S., Gesualdo, L., Cancarini, G., Feriozzi, S., Ferrario, F., Feehally, J., Coppo, R., Troyanov, S., Bellur, S.S., Cattran, D., Cook, T., Roberts, I.S., Verhave, J.C., Camilla, R., Vergano, L., Egido, J., Wiecek, A., Karkoszka, H., Tesar, V., Maixnerova, D., Ots-Rosenberg, M., Quaglia, M., Rollino, C., Magistroni, R., Cusinato, S., Cravero, R., Peruzzi, L., Lundberg, S., Gesualdo, L., Cancarini, G., Feriozzi, S., and Ferrario, F.
Abstract: Item does not contain fulltext, BACKGROUND: Tonsillectomy has been considered a treatment for IgA nephropathy (IgAN). It is aimed at removing a source of pathogens, reducing mucosa-associated lymphoid tissue and decreasing polymeric IgA synthesis. However, its beneficial effect is still controversial. In Asia, favorable outcomes have been claimed mostly in association with corticosteroids. In Europe, small, single-center uncontrolled studies have failed to show benefits. METHODS: The European validation study of the Oxford classification of IgAN (VALIGA) collected data from 1,147 patients with IgAN over a follow-up of 4.7 years. We investigated the outcome of progression to end-stage renal disease (ESRD) and/or 50% loss of estimated glomerular filtration rate (eGFR) and the annual loss of eGFR in 61 patients who had had tonsillectomy. RESULTS: Using the propensity score, which is a logistic regression model, we paired 41 patients with tonsillectomy and 41 without tonsillectomy with similar risk of progression (gender, age, race, mean blood pressure, proteinuria, eGFR at renal biopsy, previous treatments and Oxford MEST scores). No significant difference was found in the outcome. Moreover, we performed an additional propensity score pairing 17 patients who underwent tonsillectomy after the diagnosis of IgAN and 51 without tonsillectomy with similar risk of progression at renal biopsy and subsequent treatments. No significant difference was found in changes in proteinuria, or in the renal end point of 50% reduction in GFR and/or ESRD, or in the annual loss of eGFR. CONCLUSION: In the large VALIGA cohort of European subjects with IgAN, no significant correlation was found between tonsillectomy and renal function decline.
Published: 2016

32. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study

Author: Tesar, V., Troyanov, S., Bellur, S., Verhave, J.C., Cook, H.T., Feehally, J., Roberts, I.S., Cattran, D., Coppo, R., Tesar, V., Troyanov, S., Bellur, S., Verhave, J.C., Cook, H.T., Feehally, J., Roberts, I.S., Cattran, D., and Coppo, R.
Abstract: Item does not contain fulltext, Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when proteinuria is persistently >/=1 g/d despite 3-6 months of supportive care and when eGFR is >50 ml/min per 1.73 m(2). Whether the benefits of this treatment extend to patients with an eGFR
Published: 2015

33. Exome resequencing reveals ADCK4 mutations as novel causes of steroid-resistant nephrotic syndrome

Author: Ashraf, S., Gee, H. Y., Woerner, S., Xie, L. X., Vega Warner, V., Lovric, S., Fang, H., Song, X., Cattran, D., Avila Casado, C., Paterson, A. D., Nitschke, P., Cochat, C. Bole F. e. y. s. o. t. P., Esteve Rudd, J., Haberberger, B., Allen, S. J., Zhou, W., Airik, R., Otto, E. A., Barua, M., Al Hamed, M. H., Kari, J. A., Evans, J., Bierzynska, A., Saleem, M. A., Bockenhauer, D., Kleta, R., El Desoky, S., Hacihamdioglu, D. O., Gok, F., Wiggins, R. C., Lifton, M. C. h. o. i. R. P., Levy, S., Han, Z., Salviati, Leonardo, Prokisch, H., Williams, D. S., Pollak, M., Clarke, C. F., Pei, Y., Antignac, C., and Hildebrandt, F.
Published: 2013

34. RISK FACTORS FOR PROGRESSION IN CHILDREN WITH IgA NEPHROPATHY: DATA FROM A EUROPEAN COHORT

Author: Camilla, R., Coppo, R., Bellur, S., Cattran, D., Cook, T., Feehally, J., Troyanov, S., Emma, F., Giannakakis, Konstantinos, Amore, A., Mazzucco, G., Berg, U., Soderberg, M., and Mizerska Wasiak, M.
Published: 2013

35. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis

Author: Dooley, Ma, Jayne, D, Ginzler, Em, Isenberg, D, Olsen, Nj, Wofsy, D, Eitner, F, Appel, Gb, Contreras, G, Lisk, L, Solomons, N, Collaborators: Abud C, ALMS G. r. o. u. p., Adler, S, Alarc, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Menchaca, Ji, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Haya, C, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Bernard, C, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Neuwelt, Cm, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Hershey, Ms, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sánchez Guerrero, J, Sanchez Roman, J, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesaŕ, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, Zoruba, D, Houssay, B, Carson, P, Snaith, M, and Cattran, D.
Published: 2011

36. A molecular signature of proteinuria in glomerulonephritis

Author: Reich, H N, Tritchler, D, Cattran, D C, Herzenberg, A M, Eichinger, F, Boucherot, A, Henger, A, Berthier, C C, Nair, V, Cohen, C D, Scholey, J W, Kretzler, M, and University of Zurich
Subjects: 1000 Multidisciplinary, 1300 General Biochemistry, Genetics and Molecular Biology, 570 Life sciences, biology, 610 Medicine & health, 10035 Clinic for Nephrology, 1100 General Agricultural and Biological Sciences, 10052 Institute of Physiology
Published: 2010

37. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

Author: Coppo, R., Troyanov, S., Bellur, S., Cattran, D., Cook, H.T., Feehally, J., Roberts, I.S., Morando, L., Camilla, R., Tesar, V., Lunberg, S., Gesualdo, L., Emma, F., Rollino, C., Amore, A., Praga, M., Feriozzi, S., Segoloni, G., Pani, A., Cancarini, G., Durlik, M., Moggia, E., Mazzucco, G., Giannakakis, C., Honsova, E., Sundelin, B.B., Palma, A.M. De, Ferrario, F., Gutierrez, E., Asunis, A.M., Barratt, J., Tardanico, R., Perkowska-Ptasinska, A., Wetzels, J.F.M., et al., Coppo, R., Troyanov, S., Bellur, S., Cattran, D., Cook, H.T., Feehally, J., Roberts, I.S., Morando, L., Camilla, R., Tesar, V., Lunberg, S., Gesualdo, L., Emma, F., Rollino, C., Amore, A., Praga, M., Feriozzi, S., Segoloni, G., Pani, A., Cancarini, G., Durlik, M., Moggia, E., Mazzucco, G., Giannakakis, C., Honsova, E., Sundelin, B.B., Palma, A.M. De, Ferrario, F., Gutierrez, E., Asunis, A.M., Barratt, J., Tardanico, R., Perkowska-Ptasinska, A., Wetzels, J.F.M., and et al.
Abstract: Item does not contain fulltext, The Oxford Classification of IgA Nephropathy (IgAN) identified mesangial hypercellularity (M), endocapillary proliferation (E), segmental glomerulosclerosis (S), and tubular atrophy/interstitial fibrosis (T) as independent predictors of outcome. Whether it applies to individuals excluded from the original study and how therapy influences the predictive value of pathology remain uncertain. The VALIGA study examined 1147 patients from 13 European countries that encompassed the whole spectrum of IgAN. Over a median follow-up of 4.7 years, 86% received renin-angiotensin system blockade and 42% glucocorticoid/immunosuppressive drugs. M, S, and T lesions independently predicted the loss of estimated glomerular filtration rate (eGFR) and a lower renal survival. Their value was also assessed in patients not represented in the Oxford cohort. In individuals with eGFR less than 30 ml/min per 1.73 m(2), the M and T lesions independently predicted a poor survival. In those with proteinuria under 0.5 g/day, both M and E lesions were associated with a rise in proteinuria to 1 or 2 g/day or more. The addition of M, S, and T lesions to clinical variables significantly enhanced the ability to predict progression only in those who did not receive immunosuppression (net reclassification index 11.5%). The VALIGA study provides a validation of the Oxford classification in a large European cohort of IgAN patients across the whole spectrum of the disease. The independent predictive value of pathology MEST score is reduced by glucocorticoid/immunosuppressive therapy.
Published: 2014

38. Optimization of cyclosporine exposure utilizing C 2 level monitoring in de novo renal transplant recipients: the toronto general hospital experience

Author: Maham, N., Cardella, C., Cattran, D., Fenton, S., O’Grady, C., Hamill, J., Smith, R., and Cole, E.
Published: 2001
Full Text: View/download PDF

39. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy

Author: Hladunewich, M. A., primary, Cattran, D., additional, Beck, L. H., additional, Odutayo, A., additional, Sethi, S., additional, Ayalon, R., additional, Leung, N., additional, Reich, H., additional, and Fervenza, F. C., additional
Published: 2014
Full Text: View/download PDF

40. Paediatric nephrology - B

Author: Musial, K., primary, Zwolinska, D., additional, Vivarelli, M., additional, Gerken, C., additional, Pelle, T., additional, Pedicelli, S., additional, Diomedi, F., additional, Klaus, G., additional, Waldegger, S., additional, Emma, F., additional, Ronco, P., additional, Debiec, H., additional, Camilla, R., additional, Coppo, R., additional, Bellur, S., additional, Cattran, D., additional, Cook, T., additional, Feehally, J., additional, Troyanov, S., additional, Giannakakis, C., additional, Amore, A., additional, Mazzucco, G., additional, Berg, U., additional, Soderberg, M., additional, and Mizerska-Wasiak, M., additional
Published: 2013
Full Text: View/download PDF

41. Primary and secondary glomerulonephritis I

Author: Miyazaki, N., primary, Matsumoto, J., additional, Alberici, F., additional, Palmisano, A., additional, Maritati, F., additional, Oliva, E., additional, Buzio, C., additional, Vaglio, A., additional, Mjoen, G., additional, Norby, G. E., additional, Vikse, B. E., additional, Svarstad, E., additional, Rune, B., additional, Knut, A., additional, Szymczak, M., additional, Kuzniar, J., additional, Kopec, W., additional, Marchewka, Z., additional, Klinger, M., additional, Arrizabalaga, P., additional, Silvarino, R., additional, Sant, F., additional, Espinosa, G., additional, Sole, M., additional, Cervera, R., additional, Gude, D., additional, Chennamsetty, S., additional, Demin, A., additional, Kozlov, V., additional, Lisukov, I., additional, Kotova, O., additional, Sizikov, A., additional, Sergeevicheva, V., additional, Demina, L., additional, Borjesson, O., additional, Wendt, M., additional, Avik, A., additional, Qureshi, A. R., additional, Bratt, J., additional, Miller, E. J., additional, Gunnarsson, I., additional, Bruchfeld, A., additional, Sugiyama, K., additional, Hasegawa, M., additional, Yamamoto, K., additional, Hayashi, H., additional, Koide, S., additional, Murakami, K., additional, Tomita, M., additional, Yoshida, S., additional, Yuzawa, Y., additional, Yew, S., additional, Jayne, D., additional, Westman, K., additional, Hoglund, P., additional, Flossman, O., additional, Mahr, A., additional, Luqmani, R., additional, Robson, J., additional, Thervet, E., additional, Levi, C., additional, Guiard, E., additional, Roland, M., additional, Nochy, D., additional, Daniliuc, C., additional, Guillevin, L., additional, Mouthon, L., additional, Jacquot, C., additional, Karras, A., additional, Kimura, Y., additional, Morita, H., additional, Debiec, H., additional, Yamada, H., additional, Miura, N., additional, Banno, S., additional, Ronco, P., additional, Imai, H., additional, Shin, D. H., additional, Famee, D., additional, Koo, H. M., additional, Han, S. H., additional, Choi, K. H., additional, Yoo, T.-H., additional, Kang, S.-W., additional, Fofi, C., additional, Scabbia, L., additional, Festuccia, F., additional, Stoppacciaro, A., additional, Mene', P., additional, Shimizu, A., additional, Fukui, M., additional, MII, A., additional, Kaneko, T., additional, Masuda, Y., additional, Iino, Y., additional, Katayama, Y., additional, Fukuda, Y., additional, Kuroki, A., additional, Matsumoto, K., additional, Akizawa, T., additional, Jurubita, R., additional, Ismail, G., additional, Bobeica, R., additional, Rusu, E., additional, Zilisteanu, D., additional, Andronesi, A., additional, Motoi, O., additional, Ditoiu, V., additional, Copaci, I., additional, Voiculescu, M., additional, Irazabal, M. V., additional, Eirin, A., additional, Lieske, J. C., additional, Beck, L. H., additional, Dillon, J. J., additional, Nachman, P. H., additional, Sethi, S., additional, Erickson, S. B., additional, Cattran, D. C., additional, Fervenza, F. C., additional, Svobodova, B., additional, Hruskova, Z., additional, Janatkova, I., additional, Jancova, E., additional, Tesar, V., additional, Seo, M. S., additional, Kwon, S. H., additional, Lee, E. B., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Park, M. Y., additional, Choi, S. J., additional, Jeon, J. S., additional, Noh, H., additional, Kim, J. G., additional, Han, D. C., additional, Hwang, S. D., additional, Choi, T. Y., additional, Jin, S. Y., additional, Loiacono, E., additional, Defedele, D., additional, Puccinelli, M. P., additional, Camilla, R., additional, Gallo, R., additional, Peruzzi, L., additional, Rollino, C., additional, Beltrame, G., additional, Ferro, M., additional, Vergano, L., additional, Campolo, F., additional, Amore, A., additional, Coppo, R., additional, Knoop, T., additional, Bostad, L., additional, Leivestad, T., additional, Bjorneklett, R., additional, Teranishi, J., additional, Yamamoto, R., additional, Nagasawa, Y., additional, Shoji, T., additional, Iwatani, H., additional, Okada, N., additional, Moriyama, T., additional, Yamauchi, A., additional, Tsubakihara, Y., additional, Imai, E., additional, Rakugi, H., additional, Isaka, Y., additional, Doh, F. M., additional, Kim, S. J., additional, Han, D. S., additional, Suzuki, Y., additional, Matsuzaki, K., additional, Suzuki, H., additional, Okazaki, K., additional, Yanagawa, H., additional, Maiguma, M., additional, Muto, M., additional, Sato, T., additional, Horikoshi, S., additional, Novak, J., additional, Hotta, O., additional, Tomino, Y., additional, Gutierrez*, E., additional, Zamora, I., additional, Ballarin, J., additional, Arce, Y., additional, Jimenez, S., additional, Quereda, C., additional, Olea, T., additional, Martinez-Ara, J., additional, Segarra, A., additional, Bernis, C., additional, Garcia, A., additional, Goicoechea, M., additional, Garcia de Vinuesa, S., additional, Rojas, J., additional, Praga, M., additional, Ristovska, V., additional, Petrushevska, G., additional, Grcevska, L., additional, Satake, K., additional, Shimizu, Y., additional, Mugitani, N., additional, Honda, S., additional, Shibuya, K., additional, Shibuya, A., additional, Papale, M., additional, Rocchetti, M. T., additional, DI Paolo, S., additional, Suriano, I. V., additional, D'apollo, A., additional, Vocino, G., additional, Montemurno, E., additional, Varraso, L., additional, Grandaliano, G., additional, Gesualdo, L., additional, Huerta, A., additional, Bomback, A. S., additional, Canetta, P. A., additional, Radhakrishnan, J., additional, Herlitz, L., additional, Stokes, B., additional, D'agati, V., additional, Markowitz, G., additional, Appel, G. B., additional, Mouna, H., additional, Nasr, B. D., additional, Mrabet, I., additional, Ahmed, L., additional, Sabra, A., additional, Mohamed Ammeur, F., additional, Mezri, E., additional, Habib, S., additional, Innocenti, M., additional, Pasquariello, A., additional, Pasquariello, G., additional, Mattei, P., additional, Bottai, A., additional, Fumagalli, G., additional, Bozzoli, L., additional, Samoni, S., additional, Cupisti, A., additional, Caldin, B., additional, Hung, J., additional, Repizo, L., additional, Malheiros, D. M., additional, Barros, R., additional, Woronik, V., additional, Giammarresi, C., additional, Bono, L., additional, Ferrantelli, A., additional, Tortorici, C., additional, Licavoli, G., additional, Rotolo, U., additional, Huang, X., additional, Wang, Q., additional, Shi, M., additional, Chen, W., additional, Liu, Z., additional, Scarpioni, R., additional, Cantarini, L., additional, Lazzaro, A., additional, Ricardi, M., additional, Albertazzi, V., additional, Melfa, L., additional, Concesi, C., additional, Vallisa, D., additional, Cavanna, L., additional, Gungor, G., additional, Ataseven, H., additional, Demir, A., additional, Solak, Y., additional, Biyik, M., additional, Ozturk, B., additional, Polat, I., additional, Kiyici, A., additional, Ozer Cakir, O., additional, Polat, H., additional, Castillo, I., additional, Carreno, V., additional, Aguilar, A., additional, Madero, R., additional, Hernandez, E., additional, Bartolome, J., additional, Gea, F., additional, Selgas, R., additional, El Aggan, H. A. M., additional, El Banawy, H. S., additional, Wagdy, E., additional, Tchebotareva, N., additional, LI, O., additional, Bobkova, I., additional, Kozlovskaya, L., additional, Varshavskiy, V., additional, Golicina, E., additional, Chen, Y., additional, Gong, Z., additional, Chen, X., additional, Tang, L., additional, Zhou, J., additional, Cao, X., additional, Wei, R., additional, Koo, E. H., additional, Park, J. H., additional, Kim, H. K., additional, Kim, M. S., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, D. J., additional, Oh, H. Y., additional, Kim, Y.-G., additional, Eskova, O., additional, Shvetsov, M., additional, Golytsina, E., additional, Popova, O., additional, Quaglia, M., additional, Monti, S., additional, Fenoglio, R., additional, Menegotto, A., additional, Airoldi, A., additional, Izzo, C., additional, Rizzo, M. A., additional, Dianzani, U., additional, Stratta, P., additional, and Gianfreda, D., additional
Published: 2012
Full Text: View/download PDF

42. Primary and secondary glomerulonephritis II

Author: Valdivia Vega, R. P., primary, Perez Carlos, J., additional, LI, X., additional, Xu, X., additional, Zhang, W., additional, Ren, H., additional, Chen, N., additional, Yorioka, N., additional, Doi, T., additional, Hirashio, S., additional, Arita, M., additional, Hirabayashi, A., additional, Tilkiyan, E., additional, Chonova, E., additional, Ronchev, Y., additional, Kumchev, E., additional, Giamalis, P., additional, Spartalis, M., additional, Stangou, M., additional, Tsouchnikas, I., additional, Moysiades, D., additional, Dimopoulou, D., additional, Garyfalos, A., additional, Efstratiadis, G., additional, Memmos, D., additional, Schonermarck, U., additional, Eichhorn, P., additional, Sitter, T., additional, Wendler, T., additional, Vielhauer, V., additional, Lederer, S., additional, Fechner, K., additional, Fischereder, M., additional, Bantis, C., additional, Heering, P., additional, Kouri, N.-M., additional, Schwandt, C., additional, Kuhr, N., additional, Ivens, K., additional, Rump, L.-C., additional, Matta, V., additional, Melis, P., additional, Conti, M., additional, Cao, R., additional, Binda, V., additional, Altieri, P., additional, Asunis, A. M., additional, Catani, W., additional, Floris, M., additional, Angioi, A., additional, Congia, M., additional, Cucca, F., additional, Minerba, L., additional, Peri, M., additional, Pani, A., additional, Beck, L. H., additional, Fervenza, F. C., additional, Bomback, A. S., additional, Ayalon, R., additional, Irazabal, M. V., additional, Eirin, A., additional, Cattran, D. C., additional, Appel, G. B., additional, Salant, D. J., additional, Santoro, D., additional, Postorino, A., additional, Costantino, G., additional, Bellinghieri, G., additional, Savica, V., additional, Weiner, M., additional, Goh, S. M., additional, Mohammad, A., additional, Eriksson, P., additional, Westman, K., additional, Selga, D., additional, Salama, A., additional, Segelmark, M., additional, Chocova, Z., additional, Hruskova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Jancova, E., additional, Bednarova, V., additional, Rysava, R., additional, Tesar, V., additional, Hanzal, V., additional, Zamboch, K., additional, Grussmannova, M., additional, Svojanovsky, J., additional, Klaboch, J., additional, Kubisova, M., additional, Sevcik, J., additional, Olsanska, R., additional, Sobotkova, M., additional, Becvar, R., additional, Nemec, P., additional, Kodeda, M., additional, Jilek, D., additional, Hussain, M., additional, Dhaygude, A., additional, Cartery, C., additional, Huart, A., additional, Plaisier, E., additional, Bongard, V., additional, Montastruc, F., additional, Ronco, P., additional, Pourrat, J., additional, Chauveau, D., additional, Prasad, N., additional, Gurjar, D., additional, Bhadauria, D., additional, Sharma, R. K., additional, Gupta, A., additional, Kaul, A., additional, Jain, M., additional, Venning, M., additional, Brown, N., additional, Bruce, I., additional, Noor, S., additional, Bekker, P., additional, Potarca, A., additional, Dairaghi, D., additional, Miao, S., additional, Powers, J. P., additional, Jaen, J. C., additional, Schall, T. J., additional, Kalavrizioti, D., additional, Gerolymos, M., additional, Komninakis, D., additional, Rodi, M., additional, Mouzaki, A., additional, Kalliakmani, P., additional, Goumenos, D., additional, Choi, B. S., additional, Park, C. W., additional, Kim, Y.-S., additional, Yang, C. W., additional, Sun, I. O., additional, Qin, W., additional, Xie, L., additional, Tan, C., additional, Mian, W., additional, Fu, P., additional, Kaminskyy, V., additional, Hao, X., additional, Wang, W., additional, Cengiz, C., additional, Nur, C., additional, Nurdan, Y., additional, Selman, G., additional, Pinar, T., additional, Mehmet, T., additional, Lale, S., additional, Caliskan, S., additional, Shinzawa, M., additional, Yamamoto, R., additional, Nagasawa, Y., additional, Oseto, S., additional, Mori, D., additional, Niihata, K., additional, Fukunaga, M., additional, Yamauchi, A., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Chen, J.-S., additional, Lin, Y.-F., additional, Lin, W.-Y., additional, Shu, K.-H., additional, Chen, H.-H., additional, Wu, C.-J., additional, Yang, C.-S., additional, Tseng, T.-L., additional, Zaza, G., additional, Bernich, P., additional, Lupo, A., additional, Panizo, N., additional, Rivera, F., additional, Lopez Gomez, J. M., additional, Regn, S. R. o. G., additional, Ceresini, G., additional, Vaglio, A., additional, Urban, M. L., additional, Corradi, D., additional, Usberti, E., additional, Palmisano, A., additional, Buzio, C., additional, Zineb, H., additional, Ramdani, B., additional, Marques, L. P. J., additional, Rioja, L. D. S., additional, Rocco, R., additional, Nery, A. C. F., additional, Novaes, B. C., additional, Bridoux, F., additional, Sicard, A., additional, Labatut, D., additional, Touchard, G., additional, Sarkozy, C., additional, Vanhille, P., additional, Callard, P., additional, Essig, M., additional, Provot, F., additional, Nony, A., additional, Karras, A., additional, Agustin, C. P., additional, M Belen, H. R., additional, Carmen, C. P., additional, Eliana, O., additional, Elisa, P., additional, Luis, P., additional, Alberto, M.-C., additional, Javier, N., additional, Isabel, F., additional, Atzeni, A., additional, Fois, A., additional, Piras, D., additional, Maxia, S., additional, Sau, G., additional, Pili, G., additional, Porcu, M., additional, Derudas, D., additional, Angelucci, E., additional, Ledda, A., additional, La Nasa, G., additional, Ossareh, S., additional, Asgari, M., additional, Savaj, S., additional, Ataipour, Y., additional, Abdi, E., additional, Malakoutian, T., additional, Rajaa, R., additional, Berkchi, F. Z., additional, Haffane, L., additional, Squalli, Z., additional, Rouass, L., additional, Al Hamany, Z., additional, Ezzaitouni, F., additional, Benamar, L., additional, Bayahya, R., additional, Ouzeddoun, N., additional, Gao-Yuan, H., additional, Yao, X., additional, Xin, C., additional, Zhen, C., additional, Yong-Chun, G., additional, Qing-Wen, W., additional, Hui-Ping, C., additional, Da-XI, J., additional, De-Hua, G., additional, Wei-Xin, H., additional, Zhi-Hong, L., additional, Fatima Zahra, B., additional, Laila, H., additional, Zoubair, S., additional, Naima, O., additional, Smykal-Jankowiak, K., additional, Niemir, Z., additional, Polcyn-Adamczak, M., additional, Szramka-Pawlak, B., additional, Zaba, R., additional, Zhang, C., additional, MA, Y., additional, Shen, P., additional, Ouyang, Y., additional, Pan, X., additional, Wang, Z., additional, Feng, X., additional, and Ni, L., additional
Published: 2012
Full Text: View/download PDF

43. THE REDUCTION IN THE PERITONITIS RATE AMONG HIGH–RISK CAPD PATIENTS WITH THE USE OF THE OREOPOULOS–ZELLERMAN CONNECTOR

Author: Fenton, S. S. A., Wu, G., Bowman, C., Cattran, D. C., Manuel, A., Khanna, R., Vas, S., and Oreopoulos, D. G.
Published: 1985

44. HOME PERITONEAL DIALYSIS A MAJOR ADVANCE IN PROMOTING HOME DIALYSIS

Author: Fenton, S. S. A., Cattran, D. C., Barnes, N. M., and Waugh, K. J.
Published: 1977

45. Hyperlipidemia After Renal Transplantation: Natural History and Pathophysiology

Author: CATTRAN, D. C., STEINER, G., WILSON, D. R., and FENTON, S. S. A.
Published: 1979
Full Text: View/download PDF

46. Defective Triglyceride Removal in Lipemia Associated with Peritoneal Dialysis and Haemodialysis

Author: CATTRAN, D. C., FENTON, S. S. A., WILSON, D. R., and STEINER, G.
Published: 1976
Full Text: View/download PDF

47. The effect of oral contraceptives on the nitric oxide system and renal function

Author: Cherney, D. Z. I., primary, Scholey, J. W., additional, Cattran, D. C., additional, Kang, A. K., additional, Zimpelmann, J., additional, Kennedy, C., additional, Lai, V., additional, Burns, K. D., additional, and Miller, J. A., additional
Published: 2007
Full Text: View/download PDF

48. Late-onset acute haemorrhagic necrotizing granulomatous adenovirus tubulointerstitial nephritis in a renal allograft

Author: Alsaad, K. O., primary, Tobar, A., additional, Belanger, E., additional, Ahmad, M., additional, Cattran, D. C., additional, and Herzenberg, A. M., additional
Published: 2007
Full Text: View/download PDF

49. Outcomes research in glomerulonephritis1

Author: CATTRAN, D, primary
Published: 2003
Full Text: View/download PDF

50. Optimization of cyclosporine exposure utilizing C2 level monitoring in de novo renal transplant recipients: the toronto general hospital experience

Author: Maham, N., primary, Cardella, C., additional, Cattran, D., additional, Fenton, S., additional, O’Grady, C., additional, Hamill, J., additional, Smith, R., additional, and Cole, E., additional
Published: 2001
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

265 results on '"Cattran D"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources